Altimmune, inc. investors: pending lead plaintiff deadline in alt securities fraud class action; stockholders should contact robbins llp for information

San diego, june 20, 2024 (globe newswire) -- robbins llp reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired altimmune, inc. (nasdaq: alt) securities between december 1, 2023 and april 26, 2024. altimmune is a clinical stage biopharmaceutical company that focuses on developing treatments for obesity and liver diseases.
ALT Ratings Summary
ALT Quant Ranking